206 related articles for article (PubMed ID: 17937633)
1. Sirolimus use in de "novo renal" transplantation.
Grinyo JM; Alonso A; Arias M; Campistol JM; González Molina M; González Posada JM; Morales JM; Oppenheimer F; Sánchez Fructuoso A; Sánchez-Plumed J; Ruiz JC
Nefrologia; 2006; 26 Suppl 2():33-51. PubMed ID: 17937633
[No Abstract] [Full Text] [Related]
2. Drug therapy in the heart transplant recipient: part II: immunosuppressive drugs.
Lindenfeld J; Miller GG; Shakar SF; Zolty R; Lowes BD; Wolfel EE; Mestroni L; Page RL; Kobashigawa J
Circulation; 2004 Dec; 110(25):3858-65. PubMed ID: 15611389
[No Abstract] [Full Text] [Related]
3. Comparing an early corticosteroid/late calcineurin-free immunosuppression protocol to a sirolimus-, cyclosporine A-, and prednisone-based regimen for pancreas-kidney transplantation.
Knight RJ; Podder H; Kerman RH; Lawless A; Katz SM; Van Buren CT; Gaber AO; Kahan BD
Transplantation; 2010 Mar; 89(6):727-32. PubMed ID: 20195219
[TBL] [Abstract][Full Text] [Related]
4. [Association of everolimus with tacrolimus during the first year after heart transplantation: initial experience].
Cardona M; Castel MÁ; Farrero M; Pérez-Villa F
Med Clin (Barc); 2013 Jul; 141(2):87-8. PubMed ID: 23384432
[No Abstract] [Full Text] [Related]
5. Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study.
Ekberg H; Bernasconi C; Nöldeke J; Yussim A; Mjörnstedt L; Erken U; Ketteler M; Navrátil P
Nephrol Dial Transplant; 2010 Jun; 25(6):2004-10. PubMed ID: 20106825
[TBL] [Abstract][Full Text] [Related]
6. What does the CONVERT trial really tell us about conversion from calcineurin inhibitors to sirolimus?
Hanto DW; Chudzinski R
Transplantation; 2009 Jan; 87(2):164-5. PubMed ID: 19155968
[No Abstract] [Full Text] [Related]
7. Balancing efficacy and toxicity in kidney-transplant immunosuppression.
Leichtman AB
N Engl J Med; 2007 Dec; 357(25):2625-7. PubMed ID: 18094383
[No Abstract] [Full Text] [Related]
8. Conversion to sirolimus.
Ruiz JC; Alonso A; Arias M; Campistol JM; González Molina M; González Posada JM; Grinyo JM; Morales JM; Oppenheimer F; Sánchez Fructuoso A; Sánchez-Plumed J
Nefrologia; 2006; 26 Suppl 2():52-63. PubMed ID: 17937634
[No Abstract] [Full Text] [Related]
9. Combined sirolimus-calcineurin inhibitor immunosuppressive therapy in simultaneous heart and kidney transplantation: a retrospective analysis of a single hospital's experience.
Hsu KH; Chou NK; Tsai MK; Chi NH; Chen YS; Yu HY; Wang CH; Ko WJ; Tsao CI; Lee PH; Wang SS
Transplant Proc; 2010 Apr; 42(3):934-7. PubMed ID: 20430208
[TBL] [Abstract][Full Text] [Related]
10. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy.
Weir MR; Ward MT; Blahut SA; Klassen DK; Cangro CB; Bartlett ST; Fink JC
Kidney Int; 2001 Apr; 59(4):1567-73. PubMed ID: 11260422
[TBL] [Abstract][Full Text] [Related]
11. Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: one-year analysis of a randomized multicenter trial.
Guba M; Pratschke J; Hugo C; Krämer BK; Nohr-Westphal C; Brockmann J; Andrassy J; Reinke P; Pressmar K; Hakenberg O; Fischereder M; Pascher A; Illner WD; Banas B; Jauch KW;
Transplantation; 2010 Jul; 90(2):175-83. PubMed ID: 20463641
[TBL] [Abstract][Full Text] [Related]
12. Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids.
McDonald RA; Smith JM; Ho M; Lindblad R; Ikle D; Grimm P; Wyatt R; Arar M; Liereman D; Bridges N; Harmon W;
Am J Transplant; 2008 May; 8(5):984-9. PubMed ID: 18416737
[TBL] [Abstract][Full Text] [Related]
13. Fixed-dose sirolimus with reduced dose calcineurin inhibitor: the University of Colorado experience.
Wiseman AC; Kam I; Christians U; Jani A; Bak T; Wachs M; Chan L
Transplant Proc; 2003 May; 35(3 Suppl):122S-124S. PubMed ID: 12742482
[No Abstract] [Full Text] [Related]
14. Immunosuppression in HCV-positive liver-transplant recipients.
Chan AJ; Lake JR
Curr Opin Organ Transplant; 2012 Dec; 17(6):648-54. PubMed ID: 23128793
[TBL] [Abstract][Full Text] [Related]
15. Preliminary immunosuppression withdrawal strategies with sirolimus in children with liver transplants.
Sindhi R; Ganjoo J; McGhee W; Mazariegos G; Reyes J
Transplant Proc; 2002 Aug; 34(5):1972-3. PubMed ID: 12176651
[No Abstract] [Full Text] [Related]
16. Conversion to rapamycin in renal allograft recipients with biopsy-proven calcineurin inhibitor-induced nephrotoxicity.
Diekmann F; Waiser J; Fritsche L; Dragun D; Neumayer HH; Budde K
Transplant Proc; 2001; 33(7-8):3234-5. PubMed ID: 11750386
[No Abstract] [Full Text] [Related]
17. Pulmonary toxicity associated with sirolimus following kidney transplantation: computed tomography findings.
Davaus Gasparetto T; Marchiori E; Menezes P; Zanetti G
Nefrologia; 2010; 30(2):259-60. PubMed ID: 20393625
[No Abstract] [Full Text] [Related]
18. Reduced exposure to calcineurin inhibitors in renal transplantation.
Guba M; Jauch KW
N Engl J Med; 2008 Jun; 358(23):2518; author reply 2519-20. PubMed ID: 18525054
[No Abstract] [Full Text] [Related]
19. Nephrotoxicity of ciclosporin A: short-term gain, long-term pain?
Chapman JR; Nankivell BJ
Nephrol Dial Transplant; 2006 Aug; 21(8):2060-3. PubMed ID: 16728428
[No Abstract] [Full Text] [Related]
20. New trails in transplantation: how to exploit the potential of sirolimus in clinical transplantation.
Groth CG; Brattström C; Claesson K; Bäckman L
Transplant Proc; 1998 Dec; 30(8):4064-5. PubMed ID: 9865296
[No Abstract] [Full Text] [Related]
[Next] [New Search]
